Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)

被引:104
|
作者
Yu, Roger J. [1 ]
Krantz, Matthew S. [2 ]
Phillips, Elizabeth J. [1 ]
Stone, Cosby A., Jr. [2 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA
基金
美国国家卫生研究院;
关键词
FDA; FAERS; Anaphylaxis; Drug allergy; Death; Fatal;
D O I
10.1016/j.jaip.2020.09.021
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
BACKGROUND: Drug-induced anaphylaxis is a well-known adverse drug reaction for some drug classes, but emerging drug causes of anaphylaxis and novel mechanisms may contribute in unrecognized ways. OBJECTIVE: We sought to determine the top drugs reported in association with anaphylaxis and anaphylaxis followed by death in the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We reviewed the publicly available FAERS database from 1999 to 2019. Using search terms "anaphylactic shock" or "anaphylactic reaction" and sorting cases by generic drug names, we counted and trended reports to FAERS in which a drug was associated with anaphylaxis or anaphylaxis followed by death. RESULTS: From 1999 to 2019, there were 17,506,002 adverse drug events reported in FAERS, of which 47,496 (0.27%) were reported as anaphylaxis. Excluding patients without age, sex, or country data, respectively, the median age of patients in reports of anaphylaxis was 52 (interquartile range: 28), 62.71% were female, and 13,899 of 34,381 (40.43%) reports were from the United States. There were 2984 of 47,496 (6.28%) reports of anaphylaxis followed by death. Top drug classes associated with anaphylaxis in FAERS were antibiotics, monoclonal antibodies (mAbs), nonsteroidal anti-inflammatory drugs, and acetaminophen. Top drug classes associated with anaphylaxis deaths were antibiotics, radiocontrast agents, and intraoperative agents. Linear regression demonstrated reports of anaphylaxis to mAbs increasing at an average rate of 0.77% of total anaphylaxis reports per year (95% confidence interval: 0.65, 0.88) from 2.00% in 1999 to 17.37% in 2019, faster than any other drug class. CONCLUSION: Antibiotics were highly reported for anaphylaxis overall and anaphylaxis followed by death. Increasing reports were noted for anaphylaxis to mAb therapies. (C) 2020 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:819 / +
页数:13
相关论文
共 50 条
  • [41] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Kate E. Rees
    Te-yuan Chyou
    Prasad S. Nishtala
    Drug Safety, 2020, 43 : 607 - 609
  • [42] A DISPROPORTIONALITY ANALYSIS OF THE SERIOUS ADVERSE DRUG EVENTS ASSOCIATED WITH GENE THERAPY PRODUCTS USING THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
    Ghanem, B.
    Fleming, M.
    Brown, L. M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2023, 26 (06) : S237 - S237
  • [43] Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
    Wichelmann, Thomas A.
    Abdulmujeeb, Sufyan
    Ehrenpreis, Eli D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1290 - 1297
  • [44] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Rees, Kate E.
    Chyou, Te-yuan
    Nishtala, Prasad S.
    DRUG SAFETY, 2020, 43 (06) : 607 - 609
  • [45] Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS)
    Ángel Oteo-Álvaro
    Carlos Goicoechea García
    Alejandra Inocencio Sánchez
    Carlo Alemany Santamaria
    Javier de Diego-Adeliño
    Osteoporosis International, 2023, 34 : 1799 - 1804
  • [46] Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's adverse event reporting system and review of case reports in the literature
    Raisch, Dennis W.
    Garg, Vishvas
    Arabyat, Rasha
    Shen, Xian
    Edwards, Beatrice J.
    Miller, Frank H.
    McKoy, June M.
    Nardone, Beatrice
    West, Dennis P.
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (01) : 15 - 23
  • [47] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [48] Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS)
    Oteo-Alvaro, Angel
    Goicoechea Garcia, Carlos
    Inocencio Sanchez, Alejandra
    Alemany Santamaria, Carlo
    de Diego-Adelino, Javier
    OSTEOPOROSIS INTERNATIONAL, 2023, 34 (10) : 1799 - 1804
  • [49] ANAPHYLAXIS ADVERSE EVENTS WITH 3RD GENERATION CEPHALOSPORINS: DISPROPORTIONALITY ANALYSIS OF THE UNITED STATES FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM (FAERS)
    Pawar, A. M.
    Caffrey, A. R.
    VALUE IN HEALTH, 2014, 17 (03) : A265 - A265
  • [50] Unveiling the Hidden Toll of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
    Fusaroli, Michele
    Polizzi, Stefano
    Giunchi, Valentina
    Raschi, Emanuel
    Poluzzi, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 308 - 309